Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Stomach Neoplasms 23Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Adenocarcinoma 11Breast Neoplasms 9Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Carcinoma, Pancreatic Ductal 7Biliary Tract Neoplasms 7Lung Neoplasms 6Gallbladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Diseases 5Digestive System Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Endocrine Gland Neoplasms 4Digestive System Diseases 4Advanced Pancreatic Cancer 4Rectal Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3

Interventions

S 1 (combination) 2tislelizumab 1sintilimab 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Doxorubicin 1Cisplatin 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Peritoneal Metastases × Albumin-Bound Paclitaxel × Gastrointestinal × Clear all
NCT06487715 2024-07-05

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
42 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡